J&J cuts Nizoral to focus on core lines
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Johnson & Johnson (J&J) is offloading the rights to the Nizoral dandruff treatment in three separate deals as part of its strategy to divest non-core assets and focus on its larger Consumer brands.
You may also be interested in...
EU Business Round-Up: Galenica Boosted By Deals, Alliance's Sales Rise, And Beiersdorf Relaunches Wound Care
Latest EU business news: Galenica posts sales up in 2020 thanks to deals; Alliance Pharma's Consumer sales edge up despite COVID-19; and Beiersdorf is relaunching its wound care range with sustainability in mind.
German OTC Marketing Round-Up, May: Stada, Pohl Boskamp, Bene And Almirall
This month’s round-up of German OTC marketing news features a line extension and a post-acquisition re-launch from Stada, a new flavor Gelo Revoice and advertising campaign for Nyda from Pohl Boskamp, a "large scale" marketing campaign for Bene's ear-care range, and Almirall's latest efforts to promote its foot-care range.
J&J Names New EMEA Chief To Drive Consumer Growth
J&J has turned to long-serving exec Pat Smallcombe to drive growth and market share for its Consumer business in Europe, the Middle East and Africa.